Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
12 2019
Historique:
received: 24 03 2019
accepted: 21 06 2019
pubmed: 28 7 2019
medline: 2 9 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

Astroblastoma (ABM) is a rare glial brain tumor. Recurrent meningioma 1 (MN1) alterations have been recently identified in most pediatric cases. Adolescent and adult cases, however, remain molecularly poorly defined. We performed clinical and molecular characterization of a retrospective cohort of 14 adult and 1 adolescent ABM. Strikingly, we found that MN1 fusions are a rare event in this age group (1/15). Using methylation profiling and targeted sequencing, most cases were reclassified as either pleomorphic xanthoastrocytomas (PXA)-like or high-grade glioma (HGG)-like. PXA-like ABM show We suggest that gliomas with astroblastic features include a variety of molecularly sharply defined entities. Adult ABM harboring molecular features of PXA and HGG should be reclassified. Central nervous system high-grade neuroepithelial tumors with Astroblastoma (ABM) remains a poorly defined and controversial entity. Although meningioma 1 alterations seem to define a large subset of pediatric cases, adult cases remain molecularly poorly defined. This comprehensive molecular characterization of 1 adolescent and 14 adult ABM revealed that adult ABM histology comprises several molecularly defined entities, which explains clinical diversity and identifies actionable targets. Namely, pleomorphic xanthoastrocytoma-like ABM cases show a favorable prognosis whereas high-grade glioma (glioblastoma and diffuse midline gliome)-like ABM show significantly worse clinical courses. These results call for in-depth molecular analysis of adult gliomas with astroblastic features for diagnostic and therapeutic purposes.

Sections du résumé

BACKGROUND
Astroblastoma (ABM) is a rare glial brain tumor. Recurrent meningioma 1 (MN1) alterations have been recently identified in most pediatric cases. Adolescent and adult cases, however, remain molecularly poorly defined.
MATERIALS AND METHODS
We performed clinical and molecular characterization of a retrospective cohort of 14 adult and 1 adolescent ABM.
RESULTS
Strikingly, we found that MN1 fusions are a rare event in this age group (1/15). Using methylation profiling and targeted sequencing, most cases were reclassified as either pleomorphic xanthoastrocytomas (PXA)-like or high-grade glioma (HGG)-like. PXA-like ABM show
CONCLUSION
We suggest that gliomas with astroblastic features include a variety of molecularly sharply defined entities. Adult ABM harboring molecular features of PXA and HGG should be reclassified. Central nervous system high-grade neuroepithelial tumors with
IMPLICATIONS FOR PRACTICE
Astroblastoma (ABM) remains a poorly defined and controversial entity. Although meningioma 1 alterations seem to define a large subset of pediatric cases, adult cases remain molecularly poorly defined. This comprehensive molecular characterization of 1 adolescent and 14 adult ABM revealed that adult ABM histology comprises several molecularly defined entities, which explains clinical diversity and identifies actionable targets. Namely, pleomorphic xanthoastrocytoma-like ABM cases show a favorable prognosis whereas high-grade glioma (glioblastoma and diffuse midline gliome)-like ABM show significantly worse clinical courses. These results call for in-depth molecular analysis of adult gliomas with astroblastic features for diagnostic and therapeutic purposes.

Identifiants

pubmed: 31346129
pii: theoncologist.2019-0223
doi: 10.1634/theoncologist.2019-0223
pmc: PMC6975955
doi:

Substances chimiques

Mitogen-Activated Protein Kinases EC 2.7.11.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1584-1592

Informations de copyright

© AlphaMed Press 2019.

Déclaration de conflit d'intérêts

Disclosures of potential conflicts of interest may be found at the end of this article.

Références

Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Onco Targets Ther. 2015 Feb 19;8:451-60
pubmed: 25737639
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Clin Neurosci. 2011 Jun;18(6):750-4
pubmed: 21507653
J Neurooncol. 2009 Jul;93(3):369-78
pubmed: 19214707
Stem Cell Reports. 2015 Dec 8;5(6):946-953
pubmed: 26584541
Nature. 2014 Feb 27;506(7489):451-5
pubmed: 24553141
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
CNS Oncol. 2018 Apr;7(2):CNS13
pubmed: 29708401
Neuro Oncol. 2017 Jan;19(1):31-42
pubmed: 27416954
Cancer. 1999 May 1;85(9):2033-45
pubmed: 10223246
World Neurosurg. 2014 Jul-Aug;82(1-2):e291-7
pubmed: 24141003
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Cell. 2016 Feb 25;164(5):1060-1072
pubmed: 26919435
Genome Biol. 2013 Feb 14;14(2):R12
pubmed: 23409703
Acta Neuropathol. 2013 Dec;126(6):907-15
pubmed: 24154961
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Clin Cancer Res. 2015 Jul 15;21(14):3307-17
pubmed: 25609060
Brain Pathol. 2014 Apr;24(3):221-9
pubmed: 24345274
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Genet. 2013 Aug;45(8):927-32
pubmed: 23817572
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Neuropathology. 2015 Aug;35(4):303-11
pubmed: 25786545
Brain Pathol. 2019 Jan;29(1):85-96
pubmed: 30051528
Acta Neuropathol. 2018 Nov;136(5):793-803
pubmed: 30187121
Acta Neuropathol Commun. 2019 Mar 15;7(1):42
pubmed: 30876455
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Cancer Genet. 2016 Jul-Aug;209(7-8):321-30
pubmed: 27425854
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Bioinformatics. 2016 Apr 15;32(8):1226-8
pubmed: 26656567
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
AJNR Am J Neuroradiol. 2002 Feb;23(2):243-7
pubmed: 11847049
Brain Pathol. 2018 Sep;28(5):684-694
pubmed: 28990708
Genome Med. 2015 May 11;7(1):43
pubmed: 26019724
Genome Biol. 2011 Aug 11;12(8):R72
pubmed: 21835007
Brain Pathol. 2016 Sep;26(5):569-80
pubmed: 26517431
Brain Pathol. 2018 Mar;28(2):192-202
pubmed: 28960623
Bioinformatics. 2014 Sep 15;30(18):2678-80
pubmed: 24876377
Cancer Cell. 2015 Sep 14;28(3):370-83
pubmed: 26343582
Childs Nerv Syst. 2017 Aug;33(8):1295-1302
pubmed: 28477040
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuroradiology. 2007 Mar;49(3):203-9
pubmed: 17216265
Brain Pathol. 2000 Jul;10(3):342-52
pubmed: 10885653
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
PLoS Comput Biol. 2011 May;7(5):e1001138
pubmed: 21625565

Auteurs

William Boisseau (W)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles, Foix, Service de Neurologie 2-Mazarin, Paris, France.

Philipp Euskirchen (P)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
Berlin Institute of Health, Berlin, Germany.
German Cancer Consortium (DKTK), Berlin, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Karima Mokhtari (K)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.

Caroline Dehais (C)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles, Foix, Service de Neurologie 2-Mazarin, Paris, France.

Mehdi Touat (M)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Khê Hoang-Xuan (K)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Marc Sanson (M)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Laurent Capelle (L)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Aurélien Nouet (A)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Carine Karachi (C)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France.

Franck Bielle (F)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.

Justine Guégan (J)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Yannick Marie (Y)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Nadine Martin-Duverneuil (N)

AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles, Foix, Service de Neuroradiologie, Paris, France.

Luc Taillandier (L)

Department of Neurology, Centre Hospitalo-Universitaire de Nancy, Nancy, France.

Audrey Rousseau (A)

Institut Cancérologique de l'Ouest Paul Papin, Angers, France.

Jean-Yves Delattre (JY)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Ahmed Idbaih (A)

Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France ahmed.idbaih@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH